Stable Gastric Pentadecapeptide BPC 157 Counteracts Convulsions Induced by Concomitant Application of Atypical Neuroleptic, SSRI and NSAID, Risperidone, Citalopram and Metamizole in Rats
Authors: Ilic Spomenko , Strbe Sanja , Zizek Helena , Drmic Domagoj , Seiwerth Sven , Sikiric Predrag 
Published: June 2021

We documented that stable gastric pentadecapeptide BPC 157 counteracts convulsions induced by concomitant application of atypical neuroleptic, SSRI and NSAID, risperidone, citalopram and metamizole in rats. BPC 157, LD1 not achieved, was implemented as an anti‐ulcer peptide in inflammatory bowel disease trials and now in a multiple sclerosis trial (Curr Pharm Des. 2018;24(18):1990–2001). Previously, BPC 157 counteracts consequences of dopamine (D), receptors blockade (neuroleptics‐induced catalepsy, prolonged QT intervals, sphincters dysfunction and gastric lesions), much like over‐stimulation (amphetamine acute and chronic disturbances; much like D‐receptors supersensitivity (amphetamine after haloperidol)), nigrostriatal lesions (MPTP Parkinsogenic neurotoxin), D‐vesicles depletion (reserpine) (see Sikiric et al., Brain‐gut axis and pentadecapeptide BPC 157: Theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857–865. Review). Similarly, BPC 157 counteracts immobility more than imipramine in depression‐models (Porsolt's and chronic unpredictable stress‐open field) and induces 5‐HT release in particular brain areas (nigrostriatum) when given peripherally, acute and chronically (see Sikiric et al., Brain‐gut axis and pentadecapeptide BPC 157: Theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857–865. Review). Also, BPC 157 counteracts convulsions induced by various convulsants (picrotoxine, strychnine, metrazole, bicuculline) much like either with insulin or with paracetamol (see Sikiric et al., Brain‐gut axis and pentadecapeptide BPC 157: Theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857–865. Review). In this study, we applied (mg/kg) risperidone 2.5 mg/kg, citalopram 2.0 mg/kg and metamizole 2.0 intraperitoneally. Medication (mg/kg), given 15 min before, or immediately after, includes BPC 157(0.01; 0,00001) while control rats received an equivolume of saline (5 mL/kg). Thereafter, at 20 minutes after medication risperidone/citalopram/metamizole rats became markedly sedated. Then, after the next 20 minutes they start with tonic‐clonic seizures. The seizure period was lasting for the next 3 hours. Contrarily, either of BPC 157 regimens maintained normal behavior in all rats (Figure. Presentation of risperidone 2.5 mg/kg, citalopram 2.0 mg/kg and metimizole 2.0 mg in rats. Upper. Convulsing control rats. Low. BPC 157 rats normal behavior and counteracted severe convulsions)ConclusionBPC 157 exhibits also an anti‐convulsant capacity, as well as a particular profile, which could in a therapy of neuroleptic, SSRI and NSAID intoxication.Support or Funding InformationThis work was supported by the Ministry of Science, Education and Sports, Republic of Croatia [grant number 108‐1083570‐3635].This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.